Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2020

View Archived Issues

Enrollment ongoing in phase I/II ASPEN-02 study of ALX-148 plus azacytidine in MDS

Oncostellae initiates phase Ib/IIa study of OST-122 in ulcerative colitis

Venthera begins first-in-human trial of VT-30

Drug repurposing study suggests paromomycin as a dual targeting drug against SARS-CoV-2

FKBP9P1 lncRNA is upregulated in HNSCC and its knockdown inhibits malignant progression

Microbiome metabolite affects neuropathic pain

Prying the BBB back open for improved LSD treatment

Dosing starts in phase I study of AMP-945

PENELOPE-B study of palbociclib does not meet primary endpoint

Potential MND treatments move a step forward

Galectin-7, a new biomarker for pre-eclampsia

UBAP2 as potential therapeutic target in pancreatic cancer

FDA clears IND for trials of ASC-42 for NASH

FDA issues complete response letter for Avenue's intravenous tramadol

Sorrento licenses PSC's mesenchymal stem cells for COVID-19-associated ARDS

Pivotal trial of Dupixent in children with moderate to severe asthma meets primary endpoint

SynAct advances phase IIa study of AP-1189 in rheumatoid arthritis

AstraZeneca advances AZD-7442 into phase III for COVID-19

Memorial Sloan Kettering, HHS patent ADAM 17-binding molecules

Celltrion begins phase III postexposure prophylaxis trial of CT-P59 for COVID-19

Janssen Pharmaceutica discloses new MAP4K1 inhibitors

New HDAC6 inhibitors discovered at 2681603 Ontario

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical present new ERK inhibitors

Axis Therapeutics collaborates with PharmaEssentia on TCR-T cell therapy in Taiwan

Registrational trial of penpulimab for nasopharyngeal cancer meets key endpoints

Promising cohort 2 data reported from pivotal study of Padcev in urothelial cancer

Topline data reported from EAP study with aviptadil for critical COVID-19

Phase I/II study of PLX-PAD for GvHD cleared to advance to cohort 2

New phase III trial evaluates hIVIG to treat COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...